CoChat
Sign Up
Cited by 338

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy

Wagner, Julia M., Hackanson, Björn, Lübbert, Michael, Jung, Manfred·2010·Clinical Epigenetics
DOI 10.1007/s13148-010-0012-4PMC PMC3020651
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13148-010-0012-4

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Approved HDAC inhibitors
Fig. 1 Approved HDAC inhibitorsCC BY-NC · PubMed Central
Fig. 2 Other HDAC inhibitors with a hydroxamic acid based structure
Fig. 2 Other HDAC inhibitors with a hydroxamic acid based structureCC BY-NC · PubMed Central
Fig. 3 Short-chain fatty acid HDACi
Fig. 3 Short-chain fatty acid HDACiCC BY-NC · PubMed Central
Fig. 4 HDAC inhibitors with an aminoanilide structure
Fig. 4 HDAC inhibitors with an aminoanilide structureCC BY-NC · PubMed Central
Fig. 5 Whole cell HDAC activity assay
Fig. 5 Whole cell HDAC activity assayCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 130

  1. Arts J et al (2007) R306465 is a novel potent inhibitor of class I HDACs with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer 97:1344–1353 · DOI
  2. Atjada P (2009) Delvelopment of the pan-DAC inhibitor Panobinostat (LBH589): successes and challenges. Cancer Lett 280:233–241 · DOI
  3. Badros A et al (2009) Phase I study of Vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 16:5250–5257 · DOI
  4. Bhatia R et al (2009) A phase 1 study of the HDAC inhibitor LBH589 in combination with imatinib for patients with CML in cytogenetic remission with residual disease detectable by qPCR. Blood 114:2194 · DOI
  5. Berenson JR et al (2009a) A phase 2 study of a 1-hour infusion of Romidepsin combined with bortezomib for multiple myeloma (MM) in patients with relapsed or refractory disease. J Clin Oncol 27:e19508 · DOI
  6. Berenson JR et al (2009b) A phase 1 study of oral Melphalan combined with LBH589 for patients with relapsed or refractory multiple myeloma (MM). Blood 114:1855 · DOI
  7. Bolden JE et al (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769–784 · DOI · Paper page
  8. Bonfils C et al (2008) Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. Clin Cancer Res 14:3441–3449 · DOI
  9. Blum KA et al (2009) Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol 147:507–514 · DOI
  10. Bradley D et al (2009) Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862). Cancer 115:5541–5549 · DOI
  11. Buchwald M et al (2009) HDACi - Targets beyond chromatin. Cancer Lett 280:160–167 · DOI
  12. Budde LE et al (2009) A phase 1 study of Vorinostat (V) in combination with rituximab, ifosphamide, carboplatin and etoposide (ICE) for patients with relapsed or refractory lymphoid malignancies or untreated T-or mantle cell lymphoma. Blood 114:3696 · DOI
  13. Burgess A et al (2004) Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 23:66963–67001 · DOI
  14. Catley L et al (2003) NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 102:2615–2622 · DOI
  15. Chen L et al (2002) Rad23 promotes the targeting of proteolytic substrates to the proteasome. Mol Cell Biol 22:4902–4913 · DOI
  16. Chen L et al (2009) Ubiquitin-associated (UBA) domains in Rad23 bind ubiquitin and promote inhibition of multi-ubiquitin chain assembly. EMBO Rep 2:933–938 · DOI
  17. Chung EJ et al (2006) Assays for the pharmacodynamic analysis of histone deacetylase inhibitors. Exp Opin Drug Metab Toxicol 2:213–230 · DOI
  18. Conte P et al (2009) Phase 1 trial of Panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer (mBC): preliminary safety and tolerability results. J Clin Oncol 27(Suppl):15 s
  19. Daud AI et al (2009) Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res 15:2479–2487 · DOI
  20. DeAngelo DJ et al (2009) Activity of oral Panobinostat (LBH589) in patients with myelofibrosis. Blood 114:2898 · DOI
  21. Deroanne CF et al (2002) Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21:427–436 · DOI · Paper page
  22. Fakih MG et al (2009) A phase I, pharmacokinetic and pharmacodynamic study on Vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clin Cancer Res 15:3189–3195 · DOI
  23. Fandy TE et al (2009) Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 114:2764–2773 · DOI
  24. Fantin VR et al (2008) Constitutive activation of signal transducers and activators of transcription predicts Vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res 68:3785–3794 · DOI
  25. Fotheringham S et al (2009) Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 15:57–66 · DOI · Paper page
  26. Fournel A et al (2008) MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7:759–768 · DOI
  27. Fujiwara Y et al (2009) Phase I and pharmacokinetic study of Vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. Cancer Sci 100:1728–1734 · DOI
  28. Furumai R et al (2002) FK228 (depsipeptide) as a natural prodrug that inhibits class I HDACs. Cancer Res 62:4916–4921
  29. Galanis E et al (2009) Phase II trial of Vorinostat in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study. J Clin Oncol 27:2052–2058 · DOI
  30. Galli M et al (2010) A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann Hematol 89:185–190 · DOI
  31. Ganesan A et al (2009) Epigenetic therapy; histone acetylation, DNA-methylation and anti-cancer drug discovery. Curr Cancer Drug Targets 9:963–981 · DOI
  32. Garcia-Manero G et al (2008) Phase 1 study of the histone deacetylase inhibitor Vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111:1060–1066 · DOI
  33. Garcia-Manero G et al (2009) Phase 2 study of Vorinostat in combination with idarubicin (Ida) and cytarabine (ara-C) as front line therapy in acute myelogenous leukemia or higher risk myelodysplastic syndromes (MDS). Blood 114:1055 · DOI
  34. Giaccone G et al (2009) Phase 2 study of the histone deacetylase inhibitor Belinostat in thymic malignancies. J Clin Oncol 27:7589 · DOI
  35. Glozak MA et al (2005) Acetylation and deacetylation of non-histone proteins. Gene 363:15–23 · DOI · Paper page
  36. Göttlicher M et al (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969–6978 · DOI
  37. Gojo I et al (2007) Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 109:2781–2790 · DOI
  38. Golay J et al (2007) The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia 21:1892–1900 · DOI
  39. Haberland M et al (2009) The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10:32–42 · DOI
  40. Hauschild A et al (2008) Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res 8:274–278 · DOI
  41. Heltweg B et al (2003) Nonisotopic substrate for assaying both human zinc and NAD+-dependent histone deacetylases. Anal Biochem 319:42–48 · DOI
  42. Hess-Stump H et al (2007) MS-275, a potent orally available inhibitor of histone deacetylases—the development of an anticancer agent. Int J BiochemCell Biol 39:1388–1405 · DOI
  43. Hirokawa Y et al (2005) Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance. Cancer Biol Ther 4:956–960 · DOI
  44. Hodges-Gallagher L et al (2006) Inhibition of histone deacetylase enhances the antiproliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells. Breast Cancer Res Treat 105:297–309 · DOI
  45. Hoffmann K et al (1999) A non-isotopic assay for histone deacetylase activity. Nucleic Acids Res 27:2057–2058 · DOI
  46. Hu Y et al (2010) Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound ²-phenylethyl isothiocyanate. Blood (in press) · DOI
  47. Jang ER et al (2004) The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor α negative breast cancer cells to tamoxifen. Oncogene 23:1724–1736 · DOI
  48. Jones P (2009) Histone deacetylase inhibitors. In: Sippl W, Jung M (eds) Epigenetic targets in drug discovery. Wiley VCH, New York, pp 185–223 · DOI
  49. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683–692 · DOI · Paper page
  50. Kazantsev A et al (2008) Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discovery 7:854–868 · DOI
  51. Khan O et al (2010) HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci USA 107:6532–6537 · DOI
  52. Kelly WK et al (2009) Final results of a phase 1 study of oral Belinostat (PXD101) in patients with solid tumours. J Clin Oncol 27:3531 · DOI
  53. Kilgore M et al (2010) Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer’s disease. Neuropsychopharmacology 35:870–880 · DOI · Paper page
  54. Kim Y et al (2008a) Clinically significant responses achieved with Romidepsin in treatment-refractory cutaneous T-cell lymphoma: final results from a phase 2b, international, multicenter, registration study. Blood 112:263 · DOI
  55. Kim YK et al (2008b) Histone deacetylase inhibitor apicidin-mediated drug resistance: involvement of P-glycoprotein. Biochem Biophys Res Commun 368:959–964 · DOI
  56. Kirschbaum M et al (2009) Vorinostat in combination with decitabine for the treatment of relapsed or newly diagnosed acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS): a phase 1 dose-escalation study. Blood 114:2089 · DOI
  57. La Bonte MJ et al. (2009) DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors Vorinostat and LBH589 in colon cancer cell lines. BMC Med Genomics 67 · DOI · Paper page
  58. Lafon-Hughes L et al (2008) Chromatin-remodelling mechanisms in cancer. Mutat Res 658:191–214 · DOI
  59. Leder A et al (1975) Differentiation of erythroleukemic cells in the presence of inhibitors of DNA synthesis. Science 190:893–894 · DOI
  60. Lin et al (2009) A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clin Cancer Res 15:6241–6249 · DOI
  61. Liu LT et al (2003) Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res 12:3069–3072
  62. Ma X et al (2009) Histone deacetylase inhibitors current status and overview of recent clinical trials. Drugs 69:1911–1934 · DOI
  63. Mackay HJ et al (2010) Phase II trial of the histone deacetylase inhibitor Belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer 46:1573–1579 · DOI
  64. Magner WJ et al (2000) Activation of MHC class I, II and CD40 gene expression by histone deacetylase inhibitors. J Immunol 165:7017–7024 · DOI · Paper page
  65. Mascarenhas J et al (2009) A phase 1 study of LBH589, a novel histone deacetylase inhibitor in patients with primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (post-PV/ET MF). Blood 114:308 · DOI
  66. Mazières J et al (2007) Epigenetic regulation of RhoB loss of expression in lung cancer. BMC Cancer 7:220 · DOI
  67. Michaelis M et al (2004) Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 65:520–527 · DOI
  68. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38–51 · DOI
  69. Molife LR et al (2010) Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) Romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol 1:109–113 · DOI
  70. Monks A et al (2009) Gene expression-signature of Belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts. Anticancer Drugs 20:682–692 · DOI
  71. Mudduluru G et al (2004) Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signalling and cancer metastasis by NaB. Oncogene 37:6304–6315
  72. Munster PN et al (2009a) Phase I trial of Vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer 101:1044–1050 · DOI
  73. Munster PN et al (2009b) Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase 1/2 trial of valproic acid and epirubicin/FEC. Clin Cancer Res 15:2488–2496 · DOI
  74. Munster PN et al (2009c) Phase 2 trial of the histone deacetylase inhibitor, Vorinostat, to restore hormone sensitivity to the antiestrogen tamoxifen in patients with advanced breast cancer who progressed on prior hormone therapy. J Clin Oncol 27:1075 · DOI
  75. Ninan JA et al (2009) A phase 1 study of Vorinostat in combination with bortezomib in refractory solid tumours. J Clin Oncol 27:2531 · DOI
  76. Novoty-Diermayr V et al (2010) SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther 9:642–652 · DOI
  77. Pandolfi PP (2001) Histone deacetylases and transcriptional therapy with their inhibitors. Cancer Chemother Pharmacol 48(Suppl1):S17–S19 · DOI
  78. Parsons PG et al (1997) Tumour selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells. Biochem Pharmacol 53:1719–1724 · DOI
  79. Pasqualucci L et al (2003) Molecular pathogenesis of non-Hodgkin’s lymphoma: the role of Bcl-6. Leuk Lymphoma 44(suppl 3):S5–S12 · DOI
  80. Piekarz RL et al (2009a) Phase 2 multi-institutional trial of the histone deacetylase inhibitor Romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 32:5410–5417 · DOI
  81. Piekarz RL et al (2009b) Final results of a phase 2 NCI multicenter study of Romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL). Blood 114:1657 · DOI
  82. Plumb JA et al (2003) Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2:721–728
  83. Pohlmann B et al (2009) Final results of a phase 2 trial of Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. Blood 114:920 · DOI
  84. Qui L et al (1999) Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 80:1252–1258 · DOI
  85. Raffoux E et al (2010) Phase 2 clinical trial of 5-azacytidine, valproic acid and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget 1:34–42 · DOI · Paper page
  86. Ramalingam SS et al (2009) Phase II study of Belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 4:97–101 · DOI
  87. Ramalingam S et al (2010) Carboplatin and paclitaxel in combination with either Vorinostat or placebo for first-line therapy of advanced non-small cell lung cancer. J Clin Oncol 1:56–62 · DOI
  88. Rathkopf D et al (2010) A phase 1 study of oral Panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 66:181–189 · DOI
  89. Reddy P et al (2004) Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 101:3921–3926 · DOI
  90. Ree A et al (2010) Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the pelvic radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol 11:459–464 · DOI
  91. Reguart N et al (2009) Phase 1 trial of Vorinostat in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) in patients with EGFR mutations after erlotinib progression. J Clin Oncol 27:e19057 · DOI
  92. Reid G et al (2005) Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor a, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene 24:4894–4907 · DOI
  93. Rephaeli A et al (2000) Prodrugs of butyric acid from bench to bedside: synthetic design, mechanisms of action, and clinical applications. Drug Dev Res 50:379–391 · DOI
  94. Revill P et al (2007) Panobinostat. Drugs future 32:315–322 · DOI
  95. Richon VM et al (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95:3003–3007 · DOI · Paper page
  96. Richon VM et al (2000) Histone deacetylase inhibitors selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97:10014–10019 · DOI · Paper page
  97. Rocha W et al (2005) Opposite effects of histone deacetylase inhibitors on glucocorticoid and estrogen signaling in human endometrial Ishikawa cells. Mol Pharmacol 68:1852–1862 · DOI
  98. Rocca A et al (2009) A phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer 100:28–36 · DOI
  99. Rössig L et al (2002) Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res 91:837–844 · DOI
  100. Saito A et al (1999) A synthetic inhibitor of HDAC, MS-27-275, with marked in vivo antitumor activity against human tumours. Proc Natl Acad Sci USA 96:4592–4597 · DOI
  101. San-Miguel JF et al (2009) A phase 1b, multi center, open-label dose-escalation study of oral Panobinostat (LBH589) and i.v. bortezomib in patients with relapsed multiple myeloma. Blood 114:3852 · DOI
  102. Santos-Rosa H, Caldas C (2005) Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer 41:2381–2402 · DOI
  103. Sauve AA et al (2006) The biochemistry of sirtuins. Annu Rev Biochem 75:435–465 · DOI · Paper page
  104. Schäfer EW et al (2009) A phase 2 study of Vorinostat in acute myeloid leukemia. Haematologica 94:1375–1382 · DOI
  105. Schneider BJ et al (2009) Phase 1 study of Vorinostat plus doxetacel in patients with solid tumour malignancies. J Clin Oncol 27:2528 · DOI
  106. Scott GK et al (2008) Destabilization of ERBB2 transcripts by targeting 3′ untranslated region messenger RNA associated HuR and histone deacetylase-6. Mol Cancer Res 6:1250–1258 · DOI
  107. Siegel D et al (2009) Combined Vorinostat, lenalidomide and dexamethasone therapy in patients with relapsed or refractory multiple myeloma: a phase 1 study. Blood 114:305 · DOI
  108. Spencer A et al (2009) Panobinostat plus lenalidomide and dexamethasone phase 1 trial in multiple myeloma (MM). Blood 114:8542
  109. Stimson L et al (2009) Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett 280:177–183 · DOI
  110. Suzuki T et al (1999) Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 42:3001–3003 · DOI
  111. Tabe Y et al (2006) Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood 107:1546–1554 · DOI
  112. Thomas EA et al (2008) The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington’s disease transgenic mice. Proc Natl Acad Sci USA 105:15564–15569 · DOI
  113. Trédaniel J et al (2009) Vorinostat in combination with gemcitabine and cisplatinum in patients with advanced non-small cell lung cancer (NSCLC): a phase 1 dose-escalation study. J Clin Oncol 27:8049 · DOI
  114. Van Lint C et al (1996) The expression of a small fraction of cellular gene is changed in response to histone hyperacetylation. Gene Expr 5:245–254
  115. Verdin E et al (2003) Class II histone deacetylases: versatile regulators. Trends Genet 19:286–293 · DOI · Paper page
  116. Verdin E et al (2004) Measurement of mammalian histone deacetylase activity. Meth Enzymol 377:180–196 · DOI
  117. Voorhees PM et al (2009) Vorinostat in combination with pegylated liposomal doxorubicine and bortezomib for patients with relapsed/refractory multiple myeloma: results from a phase 1 study. Blood 114:306 · DOI
  118. Voso MT et al (2009) Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 15:5002–5007 · DOI
  119. Warrell et al (1998) Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90:1621–1625 · DOI · Paper page
  120. Watanabe T et al (2010) Potential efficacy of the oral histone deacetylase inhibitor Vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci 101:196–200 · DOI
  121. Weichert W (2009) HDAC expression and clinical prognosis in human malignancies. Cancer Lett 280:168–176 · DOI
  122. Whitehead RP et al (2009) Phase 2 trial of Romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Invest New Drugs 5:469–475 · DOI
  123. Wilson PM et al (2010) A phase I/II trial of Vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemother Pharmacol 2010:979–988 · DOI
  124. Yang X et al (2001) Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α negative breast cancer cells. Cancer Res 61:7025–7029
  125. Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5:37–50 · DOI
  126. Younes A et al (2009) Efficacy of Panobinostat in phase 2 study in patients with relapsed/refractory Hodgekin lymphoma (HL) after high-dose chemotherapy with autologous stem cell transplant. Blood 114:923 · DOI
  127. Zain JM et al (2009) Final results of a phase 1 study of oral Belinostat (PXD101) in patients with lymphoma. J Clin Oncol 27:8580 · DOI
  128. Zhang Y et al (2006) Two catalytic domains are required for protein deacetylation. J Biol Chem 281:2401–2404 · DOI
  129. Zhang B et al (2010) Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with Imatinib mesylate. Cancer Cell 17:427–442 · DOI
  130. Zhou Q et al (2007) Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor α (ER) gene expression without loss of DNA hypermethylation. Cancer Biol Ther 6:64–69 · DOI

Cited by

Sorted by citations

Metadata

Authors
Wagner, J. M., Hackanson, B., Lübbert, M., & Jung, M.
Venue
Clinical Epigenetics
Publisher
Springer Science and Business Media LLC
Published
2010-11-09
Volume
1
Issue
3-4
Pages
117-136
ISSN
  • 1868-7075
  • 1868-7083
DOI
10.1007/s13148-010-0012-4
PMC
PMC3020651
Cited by
338
References
8
Language
en
Licence
www.springer.com/tdm (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review